Fig. 3: CDK4/6 inhibition enhances cisplatin efficacy in cisplatin-resistant and -sensitive GCT cells. | British Journal of Cancer

Fig. 3: CDK4/6 inhibition enhances cisplatin efficacy in cisplatin-resistant and -sensitive GCT cells.

From: CDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanisms

Fig. 3: CDK4/6 inhibition enhances cisplatin efficacy in cisplatin-resistant and -sensitive GCT cells.The alternative text for this image may have been generated using AI.

XTT data of cisplatin-resistant and -sensitive GCT cell lines 2102EP(-R) and NT27D1(-R) treated once with palbociclib (5 μM), ribociclib (15 μM) or cisplatin (5/2.5 μM) alone and in combination. Changes in viability (compared to solvent-treated controls) were measured over 96 h.

Back to article page